Infliximab Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an XX % CAGR during the forecast period for 2025-2034.
Infliximab is chimeric anti-TNF monoclonal antibody approved for the treatment of Chron’s Disease. It is also approved for the treatment of other autoimmune diseases such as Psoriasis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and others. It is marketed under the trade name of Remicade. It is developed by Jansen Biotech (Johnson & Johnson) operated as Centocor and was approved by U.S Food Drug Administration (FDA) in 1998 and by European Medicines Agency in 1999. It was originally approved for the treatment of Crohn’s Diseases however in 2011, it has been approved for various indications including rheumatoid arthritis.
The patent for infliximab has been expired in Europe in February 2015 and it will expire in the US during the end of year 2018. Biosimilars are defined as biotherapeutic product that have similar safety and efficacy as an approved biologic product. Pfizer’s Hospira subsidiary in partnership with Celltrion launched first biosimilar of infliximab i.e. Inflectra in the U.S. on April 2016 and in Europe in June 2013, thus entry of biosimilar into the market have boosted the growth of infliximab biosimilar market. Also, rising incidence and prevalence of autoimmune disease, emergence of new market players, increase in infliximab accessibility and price erosion have boosted the growth of the infliximab biosimilar market. However, stringent regulatory process for the product approval of biosimilars restrain the growth of the market. Furthermore, complex nature of the molecule, patent term extension, unavailability FDA certified manufacturing facilities and low switching tendency from brand to biosimilar hampers the growth of infliximab biosimilar market.
The infliximab biosimilars market is segmented by brand into Avsola (infliximab-axxq), Flixabi (SB2), Inflectra (infliximab-dyyb), Ixifi (infliximab-qbtx), Remicade, Zessly, Infimab (BOW015), NI-071, Infliximab BS, CMAB008 and other pipeline products. It is segmented by application into Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis and other related conditions. The market is also categorised by distribution channel into hospital pharmacy, online pharmacy, retail pharmacy and other direct distribution channels.
At regional level, the global infliximab biosimilar market is segmented into Asia Pacific, Europe, North America, Latin America, and Middle East & Africa. Europe dominate the infliximab biosimilar market owing to factors such as less stringent regulatory requirement compared to US FDA, early entry of infliximab biosimilar in European market, early loss of patent exclusivity and entry of new participants. Also, rising incidence and prevalence of chronic diseases and increase in geriatric population have boosted the growth of the infliximab biosimilar market in Europe. North America hold second position in global infliximab biosimilar market owing to strong infliximab biosimilar product pipeline, increased research and development expenditure and rising government initiatives. Asia Pacific is third promising revenue contributor which is expected to grow at rapid pace during forecast period. Countries such as Japan, India, and China are major contributor to the infliximab biosimilar market. Emerging and huge population base countries such as China and India offer tremendous market opportunities.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD XX Million |
| Revenue Forecast In 2034 | USD XX Million |
| Growth Rate CAGR | CAGR of XX % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Brand, Applications, Distribution Channel |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Amgen, Samsung Bioepis, Celltrion, Pfizer, Johnson & Johnson, Sandoz (Novartis division), Epirus Biopharmaceuticals, Nichi-Iko Pharmaceutical, Mabpharm, Biogen, Merck (MSD), Ranbaxy Laboratories (now Sun Pharma), Sorrento Therapeutics (partner), Other players. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Infliximab Biosimilar Market Snapshot
Chapter 4. Global Infliximab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Infliximab Biosimilar Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Infliximab Biosimilar Market Industry Trends
Chapter 5. Infliximab Biosimilar Market Segmentation 1: By Brand, Estimates & Trend Analysis
5.1. Market Share by Brand, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Brand:
5.2.1. Avsola (infliximab-axxq)
5.2.2. Flixabi (SB2)
5.2.3. Inflectra (infliximab-dyyb)
5.2.4. Ixifi (infliximab-qbtx)
5.2.5. Remicade
5.2.6. Zessly
5.2.7. Infimab (BOW015)
5.2.8. NI-071
5.2.9. Infliximab BS
5.2.10. CMAB008
5.2.11. Others (Products approved in developing countries & pipeline products)
Chapter 6. Infliximab Biosimilar Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Crohn’s Disease
6.2.2. Psoriatic Arthritis
6.2.3. Rheumatoid Arthritis
6.2.4. Ulcerative Colitis
6.2.5. Ankylosing Spondylitis
6.2.6. Plaque Psoriasis and others
Chapter 7. Infliximab Biosimilar Market Segmentation 3: By Distribution Channel, Estimates & Trend Analysis
7.1. Market Share by Distribution Channel, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
7.2.1. Hospital Pharmacy
7.2.2. Online Pharmacy
7.2.3. Retail Pharmacy
7.2.4. Other Direct Distribution Channels
Chapter 8. Infliximab Biosimilar Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Infliximab Biosimilar Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.2.3. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.3. Europe
8.3.1. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.3.3. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.4.3. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.5. Latin America
8.5.1. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.5.3. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Brand, 2021-2034
8.6.3. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa Infliximab Biosimilar Market Revenue (US$ Mn) Estimates and Forecasts by Distribution Channel, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Amgen
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Samsung Bioepis
9.2.3. Celltrion
9.2.4. Pfizer
9.2.5. Johnson & Johnson
9.2.6. Sandoz (Novartis division)
9.2.7. Epirus Biopharmaceuticals
9.2.8. Nichi-Iko Pharmaceutical
9.2.9. Mabpharm
9.2.10. Biogen
9.2.11. Merck (MSD)
9.2.12. Ranbaxy Laboratories (now Sun Pharma)
9.2.13. Sorrento Therapeutics (partner)
9.2.14. Other Prominent Players
Infliximab Biosimilar Market By Application
Infliximab Biosimilar Market By Distribution Channel
Infliximab Biosimilar Market By Region
Europe
North America:
Asia Pacific:
RoW